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Research article

Renin inhibition reduces
hypercholesterolemia-induced
atherosclerosis in mice
Hong Lu,1 Debra L. Rateri,1 David L. Feldman,2 Richard J. Charnigo Jr.,3 Akiyoshi Fukamizu,4
Junji Ishida,4 Elizabeth G. Oesterling,5 Lisa A. Cassis,1,6 and Alan Daugherty1,6
1Cardiovascular

Research Center, University of Kentucky, Lexington, Kentucky, USA. 2Novartis Institutes for Biomedical Research,
East Hanover, New Jersey, USA. 3Department of Statistics, University of Kentucky, Lexington, Kentucky, USA.
4Center for Tsukuba Advanced Research Alliance, Aspect of Functional Genomic Biology, University of Tsukuba, Tsukuba, Japan.
5Graduate Center for Toxicology and 6Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, Kentucky, USA.

The role of the renin angiotensin system (RAS) in atherosclerosis is complex because of the involvement of
multiple peptides and receptors. Renin is the rate-limiting enzyme in the production of all angiotensin peptides. To determine the effects of renin inhibition on atherosclerosis, we administered the novel renin inhibitor aliskiren over a broad dose range to fat-fed LDL receptor–deficient (Ldlr–/–) mice. Renin inhibition resulted
in striking reductions of atherosclerotic lesion size in both the aortic arch and the root. Subsequent studies demonstrated that cultured macrophages expressed all components of the RAS. To determine the role of
macrophage-derived angiotensin in the development of atherosclerosis, we transplanted renin-deficient bone
marrow to irradiated Ldlr–/– mice and observed a profound decrease in the size of atherosclerotic lesions. In
similar experiments, transplantation of bone marrow deficient for angiotensin II type 1a receptors failed to
influence lesion development. We conclude that renin-dependent angiotensin production in macrophages
does not act in an autocrine/paracrine manner. Furthermore, in vitro studies demonstrated that coculture
with renin-expressing macrophages augmented monocyte adhesion to endothelial cells. Therefore, although
previous work suggests that angiotensin peptides have conflicting effects on atherogenesis, we found that
renin inhibition profoundly decreased lesion development in mice.
Introduction
There is evolving complexity in the renin angiotensin system (RAS)
because of the identification of a spectrum of bioactive angiotensin peptides including AngII, AngIII, AngIV, and Ang1-7 (1–3).
There is also an increasing number of receptors that have been
recognized to interact with these angiotensin peptides including
AngII type 1 (AT1) receptors, AT2 receptors, AT4 receptors, and
mas receptors (4, 5).
AngII has long been considered the major bioactive effector molecule of the RAS and has been recognized as a major contributor to
hypercholesterolemia-induced atherosclerosis (6, 7). Chronic infusion of AngII augments the size of atherosclerotic lesions in LDL
receptor–deficient (Ldlr–/–) and apoE–/– mice (8–11). Conversely,
pharmacological antagonists of specific components of the RAS
have decreased the extent of atherosclerosis. Many studies have
demonstrated that angiotensin-converting enzyme (ACE) inhibitors and AT1 receptor antagonists reduce atherosclerotic lesion
size (7, 12–15). However, a mechanistic basis for the beneficial
effects observed with ACE inhibitors and AT1 receptor antagonists
has not been defined. It is currently unclear whether the efficacy is
due to inhibition of AngII production, the effect of AngII on AT2
receptors, or the continued presence of other bioactive angiotenNonstandard abbreviations used: ACE, angiotensin-converting enzyme; AT1 receptor, AngII type 1 receptor; HPF, high-power field; LDLR, LDL receptor; RAS, renin
angiotensin system.
Conflict of interest: Alan Daugherty and Lisa A. Cassis received research support
from Novartis Institutes for Biomedical Research. David L. Feldman is an employee of
Novartis Institutes for Biomedical Research.
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sin peptides that interact with receptors other than AT1 receptors.
Renin is not only the rate-limiting enzyme in AngII formation,
but also shows remarkable substrate specificity for angiotensinogen, making it an attractive target for therapeutic inhibition of all
angiotensin peptides. Thus, renin inhibition may provide a unique
approach to define the role of angiotensin peptides in the development of atherosclerosis.
In addition to the systemic RAS, it has now been recognized that
several tissues express components of the RAS and possess the
ability to synthesize AngII (16–20). With regard to atherosclerosis,
all components of the classical RAS pathway have been identified
in lesions and are associated predominantly with macrophages (6,
21–23). The presence of mRNA and protein for RAS components
has also been detected in cultured macrophages (24–26). Although
there are several potential sources of angiotensin peptides, the
relative contribution to lesion formation of systemic versus local
sources has not been defined.
Recent studies have demonstrated that AT1a receptors have a
profound effect on atherosclerosis generated by hypercholesterolemia alone (6, 7) or in combination with AngII infusion (11).
Angiotensin peptides, particularly AngII, have well-defined effects
on several cell types present in atherosclerosis. These effects are
particularly prominent for smooth muscle cells and endothelium,
with less prominent effects on macrophages (11, 27, 28). To date,
the contribution of AT1a receptors on specific cell types to the
atherogenic process has not been determined unequivocally.
The purpose of the current study was to determine whether
whole-body inhibition of renin decreases atherosclerotic lesion size.
Furthermore, we determined whether macrophage expression of
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Table 1
Effects of renin inhibition in Ldlr–/– mice fed a fat-supplemented diet for 12 weeks
Vehicle
n
Body wt (g)
Plasma cholesterol (mg/dl)
Plasma aliskiren (μM)
Plasma renin (ng/ml/30 min)
Plasma aldosterone (pg/ml)

Aliskiren
(2.5 mg/kg/d)

Aliskiren
(25 mg/kg/d)

Aliskiren
(50 mg/kg/d)

14
28.9 ± 1.4
1,288 ± 109
0.03 ± 0.005A
31.7 ± 4.5A
330 ± 55

16
29.3 ± 0.7
1,225 ± 129
0.71 ± 0.23A,B
31.9 ± 2.9A
229 ± 24

6
29.9 ± 0.7
1,201 ± 102
0.73 ± 0.09A,B
33.0 ± 2.9A
ND

15
32.3 ± 1.3
1,185 ± 93
0
13.8 ± 2.7
260 ± 22

Values are mean ± SEM. ND, not determined. AP < 0.0001 versus vehicle. BP < 0.0001 versus 2.5 mg/kg/d aliskiren.

renin contributed to the development of atherosclerosis by generating chimeric mice with renin deficiency in bone marrow–derived
cells. Finally, we also defined autocrine/paracrine effects of locally
synthesized angiotensin peptides on AT1a receptors in the development of atherosclerosis.

pressure, although there was a decrease at 1 interval measured.
Because we have previously demonstrated that hypercholesterolemia caused a mild increase in blood pressure associated with activation of the RAS (6), we also sought to determine the effect of the
50-mg/kg/d aliskiren dose on systolic blood pressure in wild-type
C57BL/6 male mice fed normal laboratory diet. The basal systolic
blood pressure in these normolipidemic mice was less than that
in strain-, age-, and gender-matched fat-fed Ldlr–/– mice. Administration of the highest dose of aliskiren did not change systolic
blood pressures in normolipidemic C57BL/6 mice, whereas both
the 25- and 50-mg/kg/d doses reduced systolic blood pressures in
hypercholesterolemic Ldlr–/– mice to the level observed in normolipidemic C57BL/6 mice (Figure 3).
Atherosclerotic lesion size was measured in both the aortic
intima by the en face technique and in sections of aortic root.
Reductions in atherosclerosis were profound in both regions, with
significant reductions in atherosclerotic lesion size observed in
mice administered the 2.5-mg/kg/d dose of aliskiren. The 25- and
50-mg/kg/d doses produced similar results, with near ablation of

Results
Systemic renin inhibition strikingly reduced atherosclerosis. Aliskiren, an octanamide, is the first representative of a new class of
nonpeptide, low–molecular weight renin inhibitors. Its action
decreases plasma concentrations of AngII, which causes depression of negative feedback of renin secretion from the kidney and
results in increased plasma renin concentrations (29–31). In this
study, aliskiren was administered at 3 different doses to produce
increasing systemic inhibition of renin. Aliskiren produced no
changes in body weight, plasma cholesterol concentrations,
plasma aldosterone concentrations (Table 1), or lipoprotein-cholesterol distribution (data not shown) in Ldlr –/– mice. The lowest dose of aliskiren, 2.5 mg/kg/d, gave plasma concentrations
that were 5-fold higher than the IC50 against
mouse renin (6.22 ± 2.25 nM), while the
higher doses of 25 and 50 mg/kg/d gave similar plasma concentrations that were 100-fold
above the IC50 (Table 1). All doses of aliskiren
increased plasma renin concentrations. Renal
renin mRNA increased in a dose-dependent
manner (P < 0.0001; Figure 1). Conversely,
mRNA abundances of angiotensinogen, ACE,
ACE2, AT1a receptors, and AT2 receptors did
not change in renal tissue (Supplemental Figure 1; supplemental material available online
with this article; doi:10.1172/JCI32970DS1).
Renin inhibition was further demonstrated
by the decreased plasma concentrations of
angiotensin peptides (Figure 2). Infusion of
2.5 mg/kg/d aliskiren, the lowest dose tested,
reduced plasma AngII and the sum of angiotensin peptide concentrations, while the
infusion of 25 mg/kg/d led to near ablation
of all peptides in plasma (Figure 2).
There was a sustained decrease in systolic
Figure 1
blood pressure during aliskiren infusion at 25
Renin inhibition dose-dependently increased renal renin mRNA abundance. Renin mRNA
and 50 mg/kg/d (P < 0.0001; Figure 3). The abundance (renin/18S rRNA ratio) was quantified by real-time PCR (n = 5 per group). mRNA
administration of 2.5 mg/kg/d aliskiren did bands by gel electrophoresis are also shown; the lanes were run on the same gel but were
not produce an overall statistically signifi- noncontiguous. Data are mean ± SEM. *P < 0.0001 versus vehicle; #P < 0.0001 versus
cant sustained reduction in systolic blood 2.5 mg/kg/d aliskiren.
The Journal of Clinical Investigation    http://www.jci.org    Volume 118    Number 3    March 2008
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Figure 2
Renin inhibition dose-dependently decreased angiotensin peptide concentrations in mouse plasma. Angiotensin peptides in mouse plasma
were resolved by HPLC and quantified with radioimmunoassay (n = 4
per group). Data are mean ± SEM. *P < 0.05 versus vehicle; #P < 0.05
versus 2.5 mg/kg/d aliskiren.

lesion formation in the aortic arch (Figure 4A). The administration
of aliskiren also profoundly reduced atherosclerotic lesion size
throughout the aortic root (vehicle, 0.16 ± 0.02 mm2; 2.5 mg/kg/d,
0.09 ± 0.01 mm2; 25 mg/kg/d, 0.07 ± 0.01 mm 2; 50 mg/kg/d,
0.05 ± 0.01 mm2; P < 0.0001; Figure 4B). All doses of aliskiren produced similar reductions in lesion size in this region.
Increased blood pressure is a consistent risk factor for the development of atherosclerotic diseases in humans (32). Thus, we
investigated the association between systolic blood pressure and
atherosclerotic lesion size in both aortic arch and root in mice
administered different doses of aliskiren. First, we calculated
Pearson correlations between systolic blood pressure and (logtransformed) atherosclerotic lesion size within each of the 4 study
groups. There were no significant correlations between systolic
blood pressure and atherosclerotic lesion size in either aortic arch
or root (data not shown). We also used linear regression to express
atherosclerotic lesion size in terms of study group assignment and
systolic blood pressure (Supplemental Figure 2). Even with adjustment for differences in systolic blood pressure, all doses of aliskiren still significantly reduced atherosclerotic lesion size in both
the aortic arch and root (P < 0.001). On the other hand, systolic
blood pressure did not predict atherosclerotic lesion size once we
controlled for aliskiren dosage.
Immunostaining of atherosclerotic tissue in aortic roots was
performed to determine whether reductions in lesion size during
renin inhibition were accompanied by changes in cell composition.
Immunostaining of lesions demonstrated that the predominance
of macrophages in vehicle-infused mice was similar in aliskireninfused mice (Figure 4C).
Systemic renin inhibition did not affect specific oxidant mechanisms.
AngII has previously been shown to promote macrophage expression of 12/15 lipoxygenase protein, which promotes atherosclerosis in Ldlr–/– mice (33, 34). The abundance of 12/15 lipoxygenase protein was determined in mouse peritoneal macrophages by
Western blotting. However, we were unable to demonstrate that
aliskiren administration had any effect on macrophage 12/15
lipoxygenase expression (data not shown). We also measured
serum titers of autoantibodies against malondialdehyde-LDL
986

(MDA-LDL), which has previously been used as an index of atherosclerosis-related oxidant mechanisms (35). However, serum
titers of MDA-LDL autoantibodies were unchanged by aliskiren
administration (data not shown).
Cultured macrophages expressed all components of RAS and synthesized
the unique precursor angiotensinogen. To determine whether macrophages express all components of the classic pathway for angiotensin peptide production, RT-PCR was used with primers that
have annealing sites across intronic boundaries for each pair (36).
mRNA expression of angiotensinogen, renin, and ACE was detected in mouse macrophages (Supplemental Figure 3A).
The ability of macrophages to secrete angiotensinogen was investigated by Western blotting (Supplemental Figure 3B). Mouse plasma protein had 2 specific bands of angiotensinogen at 52 and 64
kDa, whereas peritoneal macrophage culture medium presented a
single band at 64 kDa that was highly glycosylated, as reported previously (36). We have been unable to develop an antibody to detect
the presence of secreted renin in a Western blotting format.
The deficiency of renin has the potential to upregulate other
enzymes with similar properties, such as cathepsin D (17). However, renin deficiency had no effect on cathepsin D mRNA abundance in macrophages (Supplemental Figure 3C).
Renin deficiency in bone marrow–derived cells reduced atherosclerotic lesion
size unrelated to their AT1a receptors. Because whole-body inhibition of
renin profoundly decreased atherosclerosis, and because isolated
macrophages contain all the components for angiotensin peptide
synthesis including renin, we examined the effect of renin originating
from bone marrow–derived cells. We used the strategy of irradiating
Ldlr–/– mice and repopulating with bone marrow–derived cells from
renin+/+ or renin–/– mice. Although bone marrow has the potential
to differentiate into many cell types, this procedure predominantly
repopulates macrophages in atherosclerotic lesions (37).
In Ldlr–/– recipient mice, the renin genotype of bone marrow–
derived cells used to repopulate mice had no influence on body
weight, wbc counts, plasma cholesterol concentrations, plasma
concentrations of aldosterone and renin, or systolic blood pressure (Table 2). The chimeric nature of the mice was confirmed
at the termination of the study by genotyping the bone marrow

Figure 3
Renin inhibition decreased systolic blood pressure in Ldlr–/– mice. Systolic blood pressure was measured in Ldlr–/– mice 1 week prior to pump
implantation and during 2, 4, 8, and 12 weeks of drug administration
at the indicated doses. Aliskiren was also administered at a dose of
50 mg/kg/d to normal diet–fed Ldlr+/+ C57BL/6 mice (dotted line). Points
represent the mean of weekly observations; error bars denote SEM.
*P < 0.0001 versus vehicle; #P < 0.0001 versus 2.5 mg/kg/d aliskiren.
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Figure 4
Renin inhibition reduced atherosclerotic lesion development without
overtly altering cellular composition. (A) Atherosclerotic lesion size was
measured on the intimal surface of aortic arches. Triangles represent
individual mice; circles represent the mean; error bars denote SEM.
*P < 0.0001 versus vehicle; #P < 0.01 versus 2.5 mg/kg/d aliskiren. (B)
Atherosclerotic lesion size was measured in aortic roots. Data are represented throughout the aorta root, with transitions between the sinus
and ascending arch depicted as 0. Filled triangles, PBS vehicle (n = 14);
filled inverted triangles, 2.5 mg/kg/d aliskiren (n = 14); open triangles,
25 mg/kg/d aliskiren (n = 15); open inverted triangles, 50 mg/kg/d aliskiren (n = 6). Values are mean ± SEM. (C) Examples of atherosclerotic
lesions immunostained for macrophages and smooth muscle cells. Aortic roots were immunostained using rat anti-mouse CD68 (1:200, left),
or a rabbit anti–α-SMA (1:200, right). Original magnification, ×200.

(Figure 5A). Despite the lack of systemic changes, mice repopulated with cells derived from renin–/– mice had a large reduction in
atherosclerotic lesion size (Figure 5B). Immunostaining of lesions
demonstrated that both groups had predominantly macrophagerich lesions. Immunostaining for renin was more apparent in
Ldlr–/– mice repopulated with cells from renin+/+ mice compared
with cells from renin–/– mice (Figure 5C).
To study a potential oxidant mechanism of macrophage renin
on atherogenesis, we determined macrophage 12/15 lipoxygenase
expression. As with the aliskiren studies, we were unable to detect
an effect of renin deficiency on macrophage 12/15 lipoxygenase
expression (data not shown). We also determined whether renin
deficiency in macrophages altered lipid accumulation. Cultured
peritoneal macrophages from renin+/+ or renin–/– mice were incubated in serum-free DMEM in the presence of acetylated LDL
(20 μg/ml) for 24 hours. Staining with Oil Red O showed
intracellular accumulation of neutral lipid in both renin +/+ and
renin–/– macrophages incubated with acetylated LDL. To quantify
the cholesterol content in macrophages incubated with acetylated
LDL, we measured unesterified and esterified cholesterol by gas
chromatography–mass spectrometric analysis (GC-MS). Renin
deficiency in mouse macrophages did not result in any change in
acetylated LDL–induced increases in intracellular unesterified and
esterified cholesterol (Supplemental Figure 4).

We subsequently defined whether angiotensin peptides generated by macrophages act primarily in an autocrine/paracrine manner to promote lesion formation. Of the AT1 receptor subtypes,
only AT1a receptor was detected in macrophages (Figure 6A).
Therefore, we performed a bone marrow transplantation study
in which we irradiated Ldlr–/– mice and repopulated them with
bone marrow–derived cells from AT1a receptor+/+ or AT1a receptor–/– mice. The parameters described for the renin bone marrow
transplantation studies were also unaffected by the AT1a receptor
genotype of the bone marrow cells (Table 3). The genotype of the
peritoneal macrophages at the end of the study confirmed the chimeric nature of the mice (Figure 6B). Furthermore, in contrast to
the profound effects of renin deficiency, we failed to detect any significant effect of AT1a receptor genotype of bone marrow–derived
cells on the size of atherosclerotic lesions (Figure 6C).
Macrophage renin deficiency reduced monocyte adhesion to endothelial
cells. Because renin deficiency in bone marrow–derived cells decreased
atherosclerosis unrelated to autocrine effects on macrophage AT1a
receptors, we studied whether renin expression in macrophages
would affect adhesion of monocytes to endothelial cells, a pivotal
process in the initiation and progression of atherosclerosis. Thus,
we examined THP-1 monocyte adhesion to HUVECs. Initial studies
demonstrated that AngII (10–7 M for 24 hours) promoted monocyte
adhesion to endothelial cells (Figure 7A). AngII-induced monocyte
adhesion to HUVECs was not associated with increased endothelial
VCAM-1 expression. Although AngII failed to increase VCAM-1
expression, the ability of HUVECs to express this adhesion molecule was confirmed by incubation with TNF-α (Supplemental Figure 5). Antagonism of AngII-induced monocyte adhesion by 10–6 M
losartan demonstrated the role of AT1 receptors (Figure 7B). Having defined the role of AngII to promote adhesion, we coincubated
confluent endothelial monolayers with peritoneal macrophages
harvested from either renin+/+ or renin–/– mice that were cultured
in lower chambers of Transwell plates. Monocyte adhesion was significantly increased when HUVECs were coincubated with macrophages from renin+/+ mice compared with coincubation with macrophages from renin–/– mice (Figure 7C).
Discussion
Aliskiren effectively inhibits mouse renin and profoundly reduces atherosclerosis. The present study demonstrated that renin inhibition
reduced the size of atherosclerotic lesions in a dose-dependent
manner in Ldlr–/– mice fed a fat-enriched diet. Renin inhibition
was achieved by continuous subcutaneous infusion of the novel
inhibitor aliskiren. Aliskiren is a potent inhibitor of human

The Journal of Clinical Investigation    http://www.jci.org    Volume 118    Number 3    March 2008

987

research article
Table 2
Effects of renin deficiency in bone marrow–derived cells in
Ldlr–/– mice fed a fat-supplemented diet for 12 weeks

n
Body wt (g)
wbc count (103/μl)
Plasma cholesterol (mg/dl)
Plasma renin (ng/ml/30 min)
Plasma aldosterone (pg/ml)
Systolic BP (mmHg)

Renin+/+

Renin–/–

12
32.5 ± 0.7
8.2 ± 1.0
1,294 ± 46
12.5 ± 1.8
274.3 ± 67.5
139 ± 4

10
34.6 ± 0.9
7.5 ± 0.6
1,357 ± 54
12.0 ± 1.8
302.2 ± 91.9
137 ± 3

Values are mean ± SEM.

renin and displays species specificity for various isoforms of
renin (30). The IC50 for aliskiren against mouse renin is 1 order
of magnitude less effective than on the human enzyme (0.6 nM),
but greater than its potency against the rat enzyme (80 nM). The
plasma aliskiren concentrations achieved with doses of drug in
this study were all above the mouse IC50. Moreover, the functional inhibitory effect of aliskiren against mouse renin was demonstrated by reductions in plasma angiotensin peptide concentrations, with almost complete ablation of angiotensin peptides in
plasma at higher drug doses.
Because renin conversion of angiotensinogen to AngI is the ratelimiting step in AngII formation, renin has long been considered
the optimal target for RAS inhibition. Renin inhibition prevents
formation of all angiotensin peptides. In contrast, ACE inhibitors
do not influence non-ACE pathways such as chymase, while AT1
receptor inhibition increases circulating concentrations of angio-

tensin peptides. In this study, we found that renin inhibition by
aliskiren strikingly reduced atherosclerosis in mice. This contrasts
with the effects of AT1a receptor deficiency, which were also profound, but not as efficacious as renin inhibition (6). Also, a survey
of the literature for both ACE inhibition and AT1 receptor antagonists shows consistency with regard to reduced atherosclerotic
lesion size, but not to the level attained with renin inhibition (7,
12, 14, 15, 38, 39). However, these differences need to be substantiated by comparing the different modes of RAS inhibition within a
single study that uses multiple doses.
We have demonstrated previously that hypercholesterolemia
was associated with increased RAS activity, as indicated by large
increases in plasma concentrations of angiotensinogen and angiotensin peptides (6). In the present study, hypercholesterolemia
was associated with increased systolic blood pressure. The role of
angiotensin peptides in this elevation was demonstrated by renin
inhibition reducing systolic blood pressure to a level observed in
normolipidemic mice. Thus, there are several indications that
renin inhibition was achieved with aliskiren to a level that affected
physiological processes. Effective blockade of the RAS is associated with increased plasma renin concentrations, as demonstrated
in the current study. This systemic increase results from release
of renin in renal juxtaglomerular cells from AngII-induced negative feedback inhibition. The present results demonstrated that
such increases in plasma renin concentration during aliskiren
administration did not modulate the vasculoprotective effect of
aliskiren. With increased systemic renin concentrations, there is
the potential to interact with the recently cloned renin/prorenin
receptor to activate fibrotic pathways (40). However, the relevance
of high circulating concentrations of renin, and this receptor, to
atherogenesis is unknown.

Figure 5
Renin deficiency in bone marrow–derived cells decreased atherosclerosis in Ldlr–/– recipient mice fed a high-fat diet. (A) PCR confirmed the presence of the disrupted renin gene in bone marrow cells from recipient mice. PCR on bone marrow–derived DNA yielded an amplicon of 265 bp for the
wild-type renin allele and 386 bp for the disrupted allele. The lanes were run on the same gel but were noncontiguous. (B) Atherosclerotic lesion size
was measured on aortic arch intimal surfaces. Individual Ldlr–/– recipients are represented by open symbols. Means of each group are represented
by circles; error bars denote SEM. *P < 0.001 renin+/+ donor (n = 12) versus renin–/– donor (n = 10). (C) Renin deficiency in bone marrow–derived
cells ablated renin expression in macrophages localized to atherosclerotic lesions in the aortic root. Immunostaining was performed in the atherosclerotic lesions of aortic root using rabbit anti-mouse macrophage antisera and a chicken anti-mouse renin IgY. Original magnification, ×200.
988
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Figure 6
AT1a receptor deficiency in bone marrow–derived cells
did not alter atherosclerotic lesion size. (A) RT-PCR
confirmed that macrophages expressed mRNA of AT1a
receptors (AT1aR), but not of AT1b receptors. Examples
of positive controls (adrenal glands and aorta) and macrophages for AT1a receptors, AT1b receptors, and 18S
rRNA. Lane 1, adrenal gland; lane 2, aorta; lane 3, macrophages; lane 4, non-RT negative control in adrenal
glands. The lanes were run on the same gel but were
noncontiguous. (B) PCR confirmed the presence of
the disrupted AT1a receptor gene in mouse peritoneal
macrophages from recipient mice. PCR on macrophagederived DNA yielded an amplicon of 650 bp for wild-type
AT1a receptor and 1.1 kb for the disrupted allele. (C) Atherosclerotic lesion size was measured on aortic arch intimal surfaces. Individual symbols represent Ldlr–/– recipients. Means of each group are represented by circles;
error bars denote SEM. n = 25 (AT1a receptor+/+ donor);
24 (AT1a receptor–/– donor).

Reductions in atherosclerosis following aliskiren administration were profound in both vascular regions in which it was measured, with aortic root lesions having greater reductions than
those in aortic arches. While higher doses of aliskiren reduced
systolic blood pressure, reductions in atherosclerosis were
achieved at doses of aliskiren that showed no persistent changes
in blood pressure. In addition, we did not find any significant
correlation between systolic blood pressure and atherosclerotic lesion size after we controlled for aliskiren dosage. Previously published studies have also demonstrated that AngII-augmented atherosclerosis is not a direct consequence of its ability
to increase blood pressure. For example, while both AngII and
norepinephrine increased blood pressure to the same extent in
apoE–/– mice, only AngII accelerated atherosclerosis (10). Furthermore, the profound decreases in atherosclerotic lesion size
during administration of AT1 receptor antagonists were not
observed with either hydralazine or amlodipine when administered at doses resulting in equivalent reductions in systolic blood
pressure (7, 41). Thus, while increased systolic blood pressure is
frequently associated with atherosclerosis, the stimulus for the
hypertension appears to be the major determinant of atherogenesis rather than pressure per se (42).
AngII is well known to augment specific oxidant pathways
(43). This has been particularly well documented for the NADPH
system in smooth muscle cells (43). AngII stimulation of this
oxidant system has been consistently demonstrated to promote
smooth muscle cell hypertrophy and hyperplasia (43, 44). However, NADPH oxidase has a poorly defined role in the development of atherosclerosis. Deficiency of p47phox has previously
been noted to decrease atherosclerotic lesion size in the aortic

arch, but not the aortic root (45), while no effects were determined
in another study (46). Furthermore, gp91phox deficiency had no
effect on atherosclerotic lesion size (47). More emphasis regarding
atherogenic mechanisms has been placed on extracellular oxidant
processes that have led to the formation of protein adducts. Specific subtypes of lipoxygenases have been consistently linked to the
atherogenic process (48). Previous studies have demonstrated that
incubation of AngII with mouse peritoneal macrophages and J774
cells upregulated 12/15 lipoxygenase abundance and activity (33).
However, we were unable to demonstrate any difference in 12/15
lipoxygenase activity in macrophages from mice with profound
renin inhibition. A more general index of oxidant stress has been
the serum titers of autoantibodies to oxidatively modified proteins. Again, we were unable to detect any difference in the serum
titers of autoantibodies to one of the most commonly described
adducts, malondialdehyde. Thus, we were unable to define oxidant
stress mechanisms that were associated with the profound reduction in atherosclerosis promoted by renin inhibition.
Deficiency of AT1a receptors has previously been shown to greatly
decrease atherosclerotic lesion size in hyperlipidemic mice (6, 7).
Although no direct comparisons have been performed, the relative
extent of reductions in lesion size in the present study appeared
larger during renin inhibition than that previously observed in mice
with AT1a receptor deficiency or pharmacological blockade. Direct
comparisons of the efficacy of renin inhibition, AT1 receptor blockade, and ACE inhibition on reduction in atherosclerotic lesion size
are complicated by the definition of comparable inhibition for these
3 different mechanisms. However, the profound reductions in angiotensin peptides in this study do obviate the interpretation that the
reductions in lesion size during AT1a receptor blockade were caused
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Table 3
Effects of AT1a receptor deficiency in bone marrow–derived cells
in Ldlr–/– mice fed a fat-supplemented diet for 12 weeks

n
Body wt (g)
wbc count (103/μl)
Plasma cholesterol (mg/dl)
Plasma renin (ng/ml/30 min)

AT1a receptor+/+

AT1a receptor–/–

25
28.0 ± 0.9
11.4 ± 0.5
621 ± 43
19.8 ± 5.1

24
29.2 ± 0.7
10.5 ± 0.8
671 ± 33
27.4 ± 4.8

Values are mean ± SEM.

by enhanced stimulation of AT2 receptors (39, 49, 50). Furthermore,
these data demonstrate the benefit of inhibiting the synthesis of all
angiotensin peptides on the development of atherosclerosis.
Renin deficiency in bone marrow–derived cells decreases atherosclerosis
via the inhibition of monocyte adhesion to endothelial cells in the vascular
wall. The major source of systemic concentrations of renin is the
renal juxtaglomerular cells. While renin has been detected in several
extrarenal tissues, it is unclear whether the levels of renin produced
in extrarenal tissues is sufficient to have biological effects (20). In
a previous study, we demonstrated that renin protein was detected
by immunostaining in mouse atherosclerotic lesions (6). However,
the renin detected in lesions may result from delivery of renin from
other sources with retention by a receptor-based system (40, 51).
In the current study, we demonstrated that cultured macrophages
express a complete RAS, including renin mRNA. Furthermore, the
creation of chimeric mice with renin deficiency in infiltrating macrophages clearly demonstrated that reductions in atherosclerosis
could be achieved through deficiency of macrophage-derived renin.
Importantly, reductions in atherosclerosis were seen in chimeric
mice repopulated with renin-deficient bone marrow that exhibited
no changes in plasma renin concentrations, demonstrating a pivotal role for macrophage-derived renin in atherosclerosis.
AngII has the potential to interact with many cell types to augment the atherogenic process. These include endothelial cells,
smooth muscle cells, and macrophages. One potential mechanism
by which renin within macrophages could be exerting its effect is the
autocrine/paracrine effects of generated angiotensin peptides on
macrophages. Our present results demonstrate that the absence of
AT1a receptors in bone marrow–derived cells had no effect on lesion
size in Ldlr–/– mice. This result is consistent with previous studies in
our laboratory demonstrating that AT1a receptor deficiency in bone
marrow–derived cells had minimal effects on AngII-induced atherosclerosis (11). These results indicate that macrophages are not the
target cell type for AT1a receptors as a mediator of atherosclerosis.
The initiation and progression of atherosclerotic lesions is associated with monocyte adhesion to an intact endothelial surface (52, 53).
Consistent with previous studies (54–57), we found that AngII augmented monocyte adhesion to endothelial cells. This was inhibited
by incubation of endothelial cells with the AT1 receptor antagonist
losartan. Monocyte adhesion to endothelial cells stimulated by macrophages from renin+/+ mice was attenuated by macrophages from
renin–/– mice. These findings are consistent with macrophage-derived
angiotensin peptides contributing to atherosclerosis via the effects on
endothelial AT1 receptors. Our studies failed to demonstrate an association of augmented monocyte adhesion with increased endothelial
VCAM-1 expression. While there has been a previous report of AngII
990

increasing VCAM-1 expression in endothelial cells (58), in agreement with the present study, others have also failed to demonstrate
increased VCAM-1 (55–57, 59). Thus, the in vitro data are consistent
with AngII facilitating monocyte adhesion, although the regulator
of this effect has not been identified. Because endothelial cells possess AT1a receptors and the function of this cell type regulates lesion
development, future in vivo studies are needed to explore this axis
using AT1a receptor–floxed mice.
In conclusion, renin inhibition profoundly decreased formation
of atherosclerosis. Importantly, reductions in atherosclerosis were
evident in Ldlr–/– mice with deficiency of renin in bone marrow–
derived cells, invoking a prominent role for macrophage-derived
renin in atherosclerosis.
Methods
Mice and diet
Ldlr–/– (B6.129S7-Ldlrtm1Her, stock no. 002207), AT1a receptor–/– (B6.129P2Agtr1atm1Unc, stock no. 002682), and age-matched C57BL/6 male mice
(stock no. 000664) were obtained from The Jackson Laboratory. Male
renin–/– mice on a C57BL/6 background (N9) were generated as previously described (60). LDLR and AT1a receptor genotypes were determined by PCR as described previously (6). Renin genotyping used the

Figure 7
Renin deficiency in mouse macrophages markedly reduced monocyte
adhesion to endothelial cells. (A) AngII resulted in increased THP-1
monocyte adhesion to endothelial cells. The adhesion assay was performed by coincubation of 10–7 M AngII with HUVECs for 18 hours. Values (mean ± SEM) represent cell number of each well relative to vehicle
per HPF (n = 4 per group). *P = 0.009 versus vehicle. (B) The AT1
receptor antagonist losartan inhibited AngII-induced THP-1 monocyte
adhesion to endothelial cells. The adhesion assay was performed by
coincubation of 10–7 M AngII and 10–6 M losartan. Losartan was added
2 hours prior to the addition of AngII to cultured HUVECs. Values (mean
± SEM) represent cell number of each well relative to losartan per HPF
(n = 3 per group). *P < 0.001 versus AngII. (C) Renin deficiency resulted
in decreased THP-1 monocyte adhesion to HUVECs. Cultured peritoneal macrophages from renin+/+ or renin–/– mice were coincubated with
HUVECs for 24 hours, and an adhesion assay was then performed.
Values (mean ± SEM) represent cell number of each well relative to
renin–/– per HPF (n = 4 per group). *P = 0.03 versus renin+/+.
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following primers: 5′-ACTCTTGTTGCTCTGGAGTCCTT-3′, 5′-AGTAGTAGAAGGGGGAGTTGTGG-3′, 5′-GCTACCCGTGATATTGCTGAA-3′,
and 5′-CTTCCCAAAGCTGGCTTATTC-3′. The resultant wild-type and
deficient allele bands were 265 and 386 bp, respectively. All mice were backcrossed 10 times into a C57BL/6 background. Littermates were selected for
the studies reported in this manuscript.
All mice were maintained in a barrier facility and fed normal mouse
laboratory diet. To induce hypercholesterolemia, mice were changed to
a diet supplemented with saturated fat (milk fat 21% wt/wt) and cholesterol (0.15% wt/wt, diet no. TD88137; Harlan Teklad). All studies were
performed with the approval of the University of Kentucky Institutional
Animal Care and Use Committee.

ics (penicillin G, 100 IU/ml, and streptomycin, 100 μg/ml) overnight. Cells
were washed with serum-free DMEM to remove nonadherent cells, and
monolayers were incubated in serum-free DMEM in the presence of acetylated LDL (20 μg/ml; Intracel) for 24 hours. Macrophages were extracted
with chloroform/methanol at a 2:1 ratio with 5α-cholestane added as an
internal standard. Lipid extracts were dissolved in methylene chloride.
Unesterified cholesterol was quantified by GC-MS using a CP-3800 gas
chromatograph and a Saturn 2200 mass spectrometry (Varian) equipped
with a DB-5 MS column (J & W Scientific Inc.). Saponification was performed to determine total cholesterol. Cholesterol measurements were
normalized to cellular protein.

mRNA abundance of RAS components
Aliskiren administration
Model 2004 Alzet mini-osmotic pumps (Durect Corp.) were implanted into
male Ldlr–/– or C57BL/6 mice at the age of 6–8 weeks. Pumps were filled with
either PBS (n = 15) or solutions of aliskiren dissolved in PBS (2.5 mg/kg/d,
n = 14; 25 mg/kg/d, n = 16; 50 mg/kg/d, n = 6) and replaced at 28-day intervals
to continuously deliver solutions for a total of 12 weeks in Ldlr–/– mice (8, 9).
Aliskiren (50 mg/kg/d) was infused for 4 weeks in C57BL/6 mice (n = 8).

RNA was harvested from mouse tissues and peritoneal macrophages using
the SV Total RNA Isolation System (Promega). RT-PCR or real-time PCR
was performed as described previously (6, 36). mRNA abundances were
calculated with normalization to either 18S rRNA or β-actin. Nontemplate
and non-RT reactions were used as negative controls.

Immunostaining

This procedure was performed as described previously (11). Bone marrow
was harvested from renin+/+ or renin–/– and AT1a receptor+/+ or AT1a receptor–/– male mice (6–8 weeks old) and injected (1 × 107 cells/mouse) into
age-matched male Ldlr–/– recipient mice that had been irradiated. Four
weeks after bone marrow repopulation, recipient mice were changed to a
diet supplemented with fat for 12 weeks.

Macrophages were detected using rat anti-mouse CD68 (FA-11, catalog
no. MCA 1957; Serotec) or rabbit anti-mouse macrophage serum (catalog
no. AIA31240; Accurate Chemical Company) as described previously (6).
Smooth muscle cells and endothelial cells were detected using rabbit anti–
α-SMA (catalog no. ab5694; Abcam) and biotin-conjugated rat anti-mouse
CD31 monoclonal antibody (PECAM-1, catalog no. 553371; BD Biosciences
— Pharmingen), respectively. Immunostaining was performed on frozen sections, with appropriate negative controls, as described previously (64, 68).

Systolic blood pressure measurements

Adhesion assay

Systolic blood pressure was measured using the Visitech tail cuff system
(BP-2000 Visitech Systems) as described previously (38, 61). Systolic blood
pressure measurements were performed 1 week before osmotic pump
implantation and 2, 4, 8, and 12 weeks after implantation or 4, 8, and 12
weeks after bone marrow transplantation.

HUVECs were isolated from human umbilical cords obtained from the University of Kentucky Labor and Delivery unit and cultured in M199 media
supplemented with 20% FBS as described previously (69). Passages 1–5 were
grown to confluence in cell culture inserts coated with human fibronectin
(catalog no. 354492; BD). Plates were washed with PBS, and monolayers
were incubated in M199 media with FBS (1% vol/vol) overnight. Cells were
incubated for 24 hours with AngII (10–7 M), losartan (10–6 M), or peritoneal
macrophages from renin+/+ or renin–/– mice placed in the lower chamber.
Adhesion assays were performed as described by Huber et al. (70). Briefly,
THP-1 cells were stimulated by TNF-α (10 ng/ml) and then labeled with
calcein AM (catalog no. C-3099; Invitrogen). Labeled cells (5 × 104 /well)
were added to the upper chamber of each well. After incubating for 30 minutes at 37°C, unbound cells were washed off, and bound THP-1 cells were
fixed with glutaraldehyde (1% wt/vol). Bound monocytes were counted by
an inverted phase-contrast microscope. A minimum of 4 high-power fields
(HPFs) of each well were counted by at least 2 observers that were blinded to
the experimental design. The percent adhesion was calculated as the mean
cell number of each well relative to the mean cell number of vehicle.

Irradiation and bone marrow repopulation

Measurement of plasma components
Lipid. Plasma cholesterol concentrations and lipoprotein cholesterol distributions were determined as described previously (9).
RAS. Concentrations of angiotensin peptides were determined by resolving plasma by HPLC and performing a radioimmunoassay on the fractions
as described previously (62). Plasma renin and aldosterone concentrations
were measured as described previously (6). For determination of the IC50
for aliskiren, plasma (8 μl) from 3-month fat-fed Ldlr–/– mice (n = 3) was
incubated with an excess of rat angiotensinogen in the absence and presence of aliskiren (0.01–100 nM) for 30 minutes at 37°C. AngI was measured by radioimmunoassay (Diagnostic Systems Laboratories).
Aliskiren concentration. Plasma concentrations of aliskiren were measured
by liquid chromatography/mass spectrometry as described previously (63).
Oxidation autoantibody titers. Serum autoantibodies to MDA-LDL were
measured by ELISA as described previously (64).

Western blotting analyses

Atherosclerosis was quantified both on the aortic intima of the arch and in
the root as described previously (65, 66).

Western blotting analyses of angiotensinogen in plasma and cultured macrophage medium, and 12/15 lipoxygenase in macrophages were performed
as described previously (6, 71). Western blotting of VCAM-1 in cultured
HUVECs was performed using mouse anti-human CD106 (catalog no.
555645; BD Biosciences — Pharmingen).

Cholesterol content in macrophages

Statistics

Resident mouse peritoneal macrophages were obtained from male renin+/+
or renin–/– mice (6–8 weeks old) as described previously (67). Cells were
incubated with DMEM supplemented with 10% vol/vol FBS and antibiot-

To compare 2 groups on a continuous response variable, we used a 2-sample t test. To compare more than 2 groups on a continuous response variable, we used 1-way ANOVA; however, if the assumptions for the ANOVA

Atherosclerosis quantification

The Journal of Clinical Investigation    http://www.jci.org    Volume 118    Number 3    March 2008

991

research article
were not satisfied, we either performed the ANOVA on log-transformed
values or used the Kruskal-Wallis procedure. For repeated-measures data,
we fitted an appropriate linear mixed model. Relationships between systolic blood pressure and atherosclerotic lesion size were analyzed using
Pearson correlations and linear regression models. A P value less than 0.05
was considered statistically significant. Data are presented as mean ± SEM.
SAS version 9.1 (SAS Institute) was used to carry out data analyses.
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